ATLAS: A phase II, open-label study of rucaparib in patients (pts) with locally advanced (unresectable) or metastatic urothelial carcinoma

被引：0
|
作者：
Chowdhury, S. [1 ,2 ]
Feyerabend, S. [3 ]
Loriot, Y. [4 ]
Necchi, A. [5 ]
Gupta, S. [6 ]
Josephs, D. H. [7 ]
Rodriguez-Vida, A. [8 ]
Srinivas, S. [9 ]
Zakharia, Y. [10 ,11 ]
Nepert, D. [12 ]
Wride, K. [13 ]
Thomas, D. [14 ]
Loehr, A. [15 ]
Simmons, A. D. [15 ]
Grivas, P. [16 ]
机构：
[1] Guys Hosp, Med Oncol, London, England
[2] Sarah Cannon Res Inst, London, England
[3] Studienpraxis Urol, Urol Oncol, Nurtingen, Germany
[4] Gustave Roussy, Dept Canc Med, Canc Campus, Villejuif, France
[5] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy
[6] Univ Utah, Huntsman Canc Inst, Genitourinary Oncol Program, Salt Lake City, UT USA
[7] Guys & St Thomas Hosp, Dept Med Oncol, London, England
[8] Hosp del Mar, Genitourinary Canc Unit, Barcelona, Spain
[9] Stanford Univ, Sch Med, Urol Oncol Clin, Stanford, CA 94305 USA
[10] Univ Iowa, Div Hematol, Iowa City, IA USA
[11] Holden Comprehens Canc Ctr, Iowa City, IA USA
[12] Clovis Oncol Inc, Clin Sci, Boulder, CO USA
[13] Clovis Oncol Inc, Biostat, Boulder, CO USA
[14] Clovis Oncol Inc, Clin Operat, Boulder, CO USA
[15] Clovis Oncol Inc, Translat Med, Boulder, CO USA
[16] Univ Washington, Dept Med, Div Oncol, Seattle, WA 98195 USA
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
928TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma
    Schoffski, Patrick
    Bahleda, Rastislav
    Wagner, Andrew J.
    Burgess, Melissa A.
    Junker, Niels
    Chisamore, Michael
    Peterson, Patrick
    Szpurka, Anna M.
    Ceccarelli, Matteo
    Tap, William D.
    CLINICAL CANCER RESEARCH, 2023, 29 (17) : 3320 - 3328
  • [32] A phase II open-label study of enfortumab vedotin in patients with previously treated locally advanced, recurrent, or metastatic pancreatic adenocarcinoma (EPIC).
    Kasi, Anup
    Phadnis, Milind A.
    Al-Rajabi, Raed Moh'd Taiseer
    Baranda, Joaquina Celebre
    Li, Haoran
    Carroll, Erin
    Belcher, Cathey
    Bradbury, Shannon
    Collins, Zachary
    Sun, Weijing
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : TPS719 - TPS719
  • [33] Olaparib plus /- atezolizumab in patients with BRCA-mutated (BRCAmt) locally advanced unresectable or metastatic (advanced) breast cancer: an open-label, multicenter, randomized phase II trial
    Fanucci, Kristina A.
    Pilat, Mary Jo
    Shyr, Derek
    Shyr, Yu
    Boerner, Scott A.
    Durecki, Diane
    Noonan, Anne
    Abramson, Vandana
    Santa-Maria, Cesar
    Han, Hyo
    Nanda, Rita
    Dees, Elizabeth Claire
    Park, Haeseong
    Buys, Saundra
    Peswani, Namrata
    Chew, Helen
    Assad, Hadeel
    Wulf, Gerburg
    Richardson, Angelique
    Trivedi, Meghna S.
    Brufsky, Adam
    Abbruzzese, James
    Afghahi, Anosheh
    Sharon, Elad
    Schalper, Kurt
    LoRusso, Patricia
    CANCER RESEARCH, 2023, 83 (08)
  • [34] Re: Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results from a Phase 1/2 Open-Label Study Editorial Comment
    Chang, Sam S.
    JOURNAL OF UROLOGY, 2018, 199 (05): : 1110 - 1110
  • [35] Open label phase II study on RFS 2000 in advanced/metastatic urothelial tract tumors
    de Jonge, M
    Droz, JP
    Paz-Ares, L
    van Oosterom, A
    Fargeot, P
    Chollet, P
    Baron, B
    Lacombe, D
    Fumoleau, P
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S47 - S47
  • [36] Atezolizumab in patients (pts) with locally-advanced or metastatic urothelial carcinoma (mUC): Results from a pivotal multicenter phase II study (IMvigor 210)
    Rosenberg, J.
    Petrylak, D.
    Abidoye, O.
    Van der Heijden, M. S.
    Hofman-Censits, J.
    Necchi, A.
    O'Donnell, P. H.
    Balmanoukian, A.
    Loriot, Y.
    Retz, M.
    Perez-Gracia, J. L.
    Dawson, N. A.
    Balar, A.
    Galsky, M. D.
    Fleming, M. T.
    Powles, T.
    Cui, N.
    Mariathasan, S.
    Fine, G. D.
    Dreicer, R.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S720 - S720
  • [37] Tucidinostat plus toripalimab in patients with unresectable or metastatic melanoma: An open-label, single-arm phase II study
    Mao, Lili
    Dai, Jie
    Bai, Xue
    Kong, Yan
    Sheng, Xinan
    Chi, Zhihong
    Cui, Chuanliang
    Lian, Bin
    Tang, Bixia
    Yan, Xieqiao
    Wang, Xuan
    Li, Siming
    Zhou, Li
    Wei, Xiaoting
    Li, Juan
    Li, Caili
    Duan, Rong
    Xu, Huayan
    Guo, Jun
    Si, Lu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [38] Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b-2 study
    Finn, Richard S.
    Ryoo, Baek-Yeol
    Hsu, Chih-Hung
    Li, Daneng
    Burgoyne, Adam M.
    Cotter, Christopher
    Badhrinarayanan, Shreya
    Wang, Yulei
    Yin, Anqi
    Edubilli, Tirupathi Rao
    Mahrus, Sami
    Secrest, Matthew H.
    Shemesh, Colby S.
    Yu, Nancy
    Hack, Stephen P.
    Cha, Edward
    Gane, Ed
    LANCET ONCOLOGY, 2025, 26 (02): : 214 - 226
  • [39] Phase II Study of Gemcitabine, Carboplatin, and Bevacizumab in Patients With Advanced Unresectable or Metastatic Urothelial Cancer
    Balar, Arjun V.
    Apolo, Andrea B.
    Ostrovnaya, Irina
    Mironov, Svetlana
    Iasonos, Alexia
    Trout, Alisa
    Regazzi, Ashley M.
    Garcia-Grossman, Ilana R.
    Gallagher, David J.
    Milowsky, Matthew I.
    Bajorin, Dean F.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06) : 724 - 730
  • [40] An open-label, prospective phase II study of tislelizumab in combination with chidamide as consolidation therapy in locally advanced, unresectable, stage III NSCLC
    Hu, Y.
    Zhang, F.
    Li, T.
    Hu, Z.
    Han, X.
    Ma, Z.
    Wang, L.
    Tao, H.
    ANNALS OF ONCOLOGY, 2023, 34 : S748 - S748
12345